NCT00254137View on ClinicalTrials.gov

Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

November 30, 2006

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

capecitabine

DRUG

irinotecan

DRUG

oxaliplatin

DRUG

cetuximab

Sponsors

Collaborators (2)

Sanofi
Pfizer
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Sanofi

INDUSTRY

collaborator

Pfizer

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Ludwig-Maximilians - University of Munich

OTHER